If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Gilead buys Priority Review Voucher from Sarepta

Deal for $125 million hints at cooler market for the incentive

by Lisa M. Jarvis
February 22, 2017 | A version of this story appeared in Volume 95, Issue 9

Treasure trove

Several priority-review vouchers have yet to change hands.

Recipient: Alexion
Drug: Kanuma
Indication: Lysosomal acid lipase deficiency

Recipient: Alexion
Drug: Strensiq
Indication: Hypophosphatasia

Recipient: Biogen
Drug: Spinraza
Indication: Spinal muscular atrophy

Recipient: Johnson & Johnson
Drug: Sirturo
Indication: Multi-drug-resistant tuberculosis

Recipient: Marathon
Drug: Emflaza
Indication: Duchenne muscular dystrophy

Note: Alexion plans to keep one of its two vouchers.

Source: Companies

Gilead Sciences has paid Sarepta Therapeutics $125 million for a voucher that can speed up U.S. regulatory review of a new drug application. The price tag, modest compared to past sales, has some observers wondering whether the program is losing its luster.

Priority review vouchers were introduced in 2007 with the goal of spurring innovation in neglected tropical diseases. Expanded in 2012 to include rare childhood diseases, the program gives the developer of a drug with limited commercial potential a transferrable coupon that shaves four months off a future FDA drug review.

Until the sale of Sarepta’s PRV, the price of the vouchers had generally been on the rise. For example, Sanofi bought the first available PRV in 2014 for $67 million and later bought another one for $245 million. In 2015 AbbVie paid $350 million for its own fast-forward card.

Gilead itself has bought three PRVs, one of which it used to accelerate the approval of the HIV pill Odefsey. The company has not said how it plans to use the PRV from Sarepta, which earned it alongside approval of the Duchenne muscular dystrophy treatment Exondys 51.

A cooling in the price of PRVs is perhaps not surprising. After the rare pediatric disease PRVs were added, the number of vouchers on the market ballooned. Of the 13 PRVs handed out to date, nine are for rare drugs. Moreover, the recent passage of the 21st Century Cures Act extended the length of that pediatric program, despite protests from FDA officials who claim it has not worked as planned. The bill also added PRVs for “medical countermeasures”—treatments for biological or chemical threats.

Still, some are worried that PRVs may be losing their shine. “The price tag was even lower than our expectations of $200 million,” Leerink stock analyst Joseph Schwartz said in a note to investors. Schwartz wondered if the value is indicative of “a broader decline in PRV interest among bidders” or more narrowly of Sarepta’s failure to recognize the value of its asset.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.